Format

Send to

Choose Destination
Clin Pharmacol Ther. 2014 Apr;95(4):394-402. doi: 10.1038/clpt.2013.226. Epub 2014 Feb 19.

Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.

Author information

1
Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
2
1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA.
3
1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] Cadence Group, Atlanta, Georgia, USA.
4
Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.
5
1] Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA [2] Kelly Services, Troy, Michigan, USA.
6
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
7
Maine Dartmouth Family Medicine Residency Program, Augusta, Maine, USA.
8
1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.

Abstract

As evidence accumulates on the use of genomic tests and other health-related applications of genomic technologies, decision makers may increasingly seek support in identifying which applications have sufficiently robust evidence to suggest they might be considered for action. As an interim working process to provide such support, we developed a horizon-scanning method that assigns genomic applications to tiers defined by availability of synthesized evidence. We illustrate an application of the method to pharmacogenomics tests.

PMID:
24398597
PMCID:
PMC4689130
DOI:
10.1038/clpt.2013.226
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center